Abstract
In the search for an anti-diabetic medication that avoids the effect of hypoglycemia, a new diabetes class of medication known as the sodium glucose co transporter 2 inhibitor (SGLT2) was discovered. Invokana®(Canagliflozin) is the first FDA approved medication of its class in 2013. In conjunction with diet and exercise, it aims to improve glycemic control in patients with type 2diabetes[1]. The protein SGLT2 works by facilitating glucose reabsorption into the kidney. Inhibition of this protein leads to an increased amount of glucose excreted in the urine while simultaneously lowering blood glucose levels[2]. However, post marketing data and phase 3 trials indicated a potential for increased urinary tract infections (UTI) as collateral damage from large glucose amounts in the normally sterile urine [3].There is even a FDA safety communication that was issued in 2015 explaining the increased risk of urinary tract infections with these agents [4].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
